ChemoCentryx, Inc. Form 8-K March 14, 2013

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

# FORM 8-K

## **CURRENT REPORT**

Pursuant to Section 13 OR 15(d) of

the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 13, 2013

# CHEMOCENTRYX, INC.

(Exact name of registrant as specified in its charter)

**Delaware** (State or other jurisdiction

001-35420 (Commission 94-3254365 (IRS Employer

of incorporation) File Number) Identification No.)

## Edgar Filing: ChemoCentryx, Inc. - Form 8-K

850 Maude Avenue, Mountain View, CA
(Address of Principal Executive Offices)

Registrant s telephone number, including area code: (650) 210-2900

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any	of
the following provisions (see General Instruction A.2. below):	

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- " Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- " Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

### Edgar Filing: ChemoCentryx, Inc. - Form 8-K

#### Item 2.02 Results of Operations and Financial Condition.

On March 13, 2013, ChemoCentryx, Inc. issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2012. A copy of this press release is attached hereto as Exhibit 99.1.

In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act ), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to this Current Report on Form 8-K.

#### Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No. Description

99.1 Press Release, dated March 13, 2013

#### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CHEMOCENTRYX, INC.

Date: March 14, 2013

By: /s/ Susan M. Kanaya Name: Susan M. Kanaya

Title: Senior Vice President, Finance, Chief Financial Officer and

Secretary

#### EXHIBIT INDEX

Exhibit No. Description

99.1 Press Release, dated March 13, 2013